Restore the brain's lost dopamine supply in Parkinson's with the patient's own cells, so the graft is not rejected and no lifelong immune-suppressing drugs are needed.
Phase 1/2a fully dosed (15 patients); 12-month gains reported; preparing for phase 3.
Updated 9 Jul 2026Checked 11 Oct0 updates this week
A small skin biopsy is reprogrammed into induced pluripotent stem cells that can become any cell type.
Stem cells are guided into dopamine-neuron precursors; machine-learning genomic tests check quality at each step.
Cells go into the putamen on both sides, where dopamine is missing, through a path from the back of the head.
Because the cells are the patient's own, no immune-suppressing drugs or permanent hardware are needed.
| Spec | Sasineprocel (ANPD001) |
|---|---|
| Patients dosed (ASPIRO) | 15R (reported) |
| Extra good ON time at 12 months | +2.1 to +2.4 h/dayR (reported) |
| Motor score change (OFF, MDS-UPDRS III) | -13.5 to -15.5 pointsR (reported) |
| Cells per brain hemisphere | 5–10 millionR (reported) |
| Immunosuppression | NoneR (reported) |
R reported by the company
Aspen Neuroscience
Personalised stem-cell neurons, Parkinson's
San Diego company that turns each Parkinson's patient's own skin cells into dopamine-neuron precursors and implants them in the brain, so no immune suppression is needed.
aspenneuroscience.com (opens aspenneuroscience.com)Company profile →
